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Abstract Interleukin (IL)-5 is central in regulating eosinophilia 
in allergic disease and parasitic infections. We have recently 
shown that human (h) IL-5 both possesses a functional nuclear 
localization signal capable of targeting a heterologous protein to 
the nucleus and localises to the nucleus of intact receptor-
expressing cells. In this study, the extracellular domains of the 
hIL-5 a- and P-receptor subunits were expressed in baculovirus, 
fluorescently labelled and assayed for nuclear targeting in vitro in 
the absence and presence of IL-5. The P-siibunit, which lacks IL-
5 binding activity, only accumulated in the nucleus in the 
presence of both the hIL-5 binding a-subunit and hIL-5. The IL-
5-binding a-subunit showed similar results. IL-5 thus effected 
nuclear transport of its a- and P-receptor subunits apparently 
through a 'piggy back' mechanism, raising the possibility that 
IL-5's nuclear signalling role may be to cotarget its receptor 
subunits to the nucleus. This is the first demonstration of nuclear 
protein piggy back transport in vitro. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The cytokine interleukin (IL)-5 appears to be a quite spe-
cific differentiation factor for the eosinophil cell lineage [1-6], 
studies with an IL-5 deficient mouse suggesting that the only 
obligatory role of IL-5 may be in controlling eosinophilia in 
response to allergic diseases and certain parasitic infections 
[3,4]. The receptor for IL-5 comprises an a-subunit which 
recognises IL-5 specifically, and a P-subunit which lacks li-
gand binding activity but which is essential for signal trans-
duction [7,8]. The high affinity IL-5 receptor comprises both 
a- and P- subunits. The IL-5 P receptor subunit is shared with 
the related IL-3 and granulocyte-macrophage-colony stimulat-
ing factor (GM-CSF) receptors [7], with IL-3, IL-5 and GM-
CSF exhibiting overlapping activities on certain cell types in 
vitro as a direct consequence [7,8]. Two major signalling path-
ways mediating IL-5's effects through the receptor P-subunit 
are the JAK2 (Janus kinase 2) tyrosine phosphorylation cas-
cade leading to activation of STAT 1,3 and 5 (signal trans-
ducers and activators of transcription 1, 3 and 5) [9-13], and 
the Ras-Raf-1-MEK (mitogen-activated protein kinase -
MAPK - or Erk kinase) protein kinase pathway [11,14]. 
The existence of these two pathways does not explain IL-5's 
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very specific role in eosinophil differentiation and develop-
ment, since IL-3 and GM-CSF, which 'o not have such dis-
tinct roles, also activate both [9,10,15]. Differences in receptor 
expression (see Ref. [16]) similarly do not explain IL-5's oblig-
atory role in controlling the eosinophil lineage. 
One aspect of specificity in terms of IL-5-signalling mecha-
nisms additional to those emanating from the shared P-recep-
tor subunit resides in the fact that both human (h) and mouse 
(m) IL-5, in contrast to IL-3 and GM-CSF, possess sequences 
homologous to nuclear localization signals (NLSs) (see Ref. 
[17]). NLSs are the sequences sufficient and necessary to effect 
nuclear targeting of the proteins carrying them to the nucleus 
(see Refs. [18,19]). We have recently shown that both hIL-5 
and mIL-5 can localise in the nucleus in intact living receptor-
expressing cells subsequent to endocytosis, as well as target to 
the nucleus in in vivo and in vitro nuclear transport assays 
[20]. We also showed that the hIL-5 NLS is capable of target-
ing a heterologous protein to the nucleus both in vivo and in 
vitro, implying that it is the targeting signal responsible for 
IL-5 accumulation in the nucleus in intact cells [20]. Dimeric 
baculovirus-expressed hIL-5 is about 30 kDa, which is below 
the molecular mass cut-off (45 kDa) for an NLS-requirement 
to enter the nucleus [18,19], the possession of an NLS by IL-5 
thus possibly being necessary to target a larger complex of 
proteins to the nucleus in a 'piggy back' type of transport. 
That non-NLS-containing proteins can be targeted to the nu-
cleus through binding to an NLS-containing protein has been 
demonstrated for a number of nuclear proteins including high 
mobility group proteins and DNA polymerase subunits 
[18,19,21-24]. Importantly, the transport of one NLS-contain-
ing molecule can thus effect nuclear localization of a complex 
of specifically interacting signalling molecules [18,19]. 
In this study we investigate nuclear transport of the hIL-5 
receptor subunits in vitro in the absence and presence of IL-5 
and/or the other receptor subunit using labelled and unla-
belled baculovirus-expressed hIL-5 and soluble forms of the 
receptor subunits. The results show that IL-5 is capable of 
cotransporting its receptor subunits to the nucleus in semi-
intact cells, thus representing the first demonstration of nu-
clear protein piggy back transport in vitro. The results imply 
that there may be a nuclear signalling role for IL-5 and its 
cotargeted receptor subunits additional to pathways linked to 
the membrane receptor system. 
2. Materials and methods 
2.1. Chemicals and reagents 
The amino labelling reagent 6-(fluorescein-5-(and-6)-carboxamido)-
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hexanoic acid, succinimidyl ester (SFX) was from Molecular Probes. 
Other reagents were from the sources previously described [20,25]. 
2.2. Cell culture 
The FDC-P1 hRa cell line is a murine factor-dependent cell line 
expressing the hIL-5 receptor a-subunit which is responsive to IL-5 
owing to the presence of the mIL-5 receptor (3-subunit [20]. FDC-P1 
hRa cells were cultured in RPMI Medium supplemented with 10% 
FCS and the corresponding factor. Cells of the HTC rat hepatoma 
tissue culture line were cultured in Dulbecco's Modified Eagle's Me-
dium supplemented with 10% FCS as described previously [20,25]. 
2.3. Baculovirus expression and purification of IL-5 and receptor 
subunits 
hIL-5 was expressed using the baculovirus system in Sf9 insect cells, 
purified by gel filtration and passage through Mono Q as described 
previously [20,26]. cDNA fragments encoding the external domains of 
the hIL-5 a- and P-receptor subunits (residues 1-321 and 1^419 of the 
mature forms, respectively) were derived by PCR and subcloned into 
the transfer vector pBacPAK8 (Clontech). These recombinant pro-
teins were also expressed using the baculovirus system, and purified 
by gel filtration followed by ion exchange chromatography on Mono 
Q. The purity of the proteins was routinely verified by SDS polyacryl-
amide gel electrophoresis. 
2.4. Fluorescent labelling 
IL-5 was labelled using the covalent amine-labelling reagent SFX as 
described previously [20], whereby labelled hIL-5 retained greater than 
50% biological activity. The external domains of the hIL-5 a- and P-
receptor subunits were similarly labelled with SFX, with subsequent 
passage through a NAP-5 column (Pharmacia) to separate the la-
belled protein from free dye [20]. Protein samples were concentrated 
using 'Ultrafree-MC filter units (Millipore) [20]. 
2.5. Nuclear transport assay 
In vitro nuclear import kinetics at the single cell level, using me-
chanically perforated HTC cells in conjunction with confocal laser 
scanning microscopy (CLSM), was as described previously in detail 
[25,27] and in particular for hIL-5 [20]. Where combinations of re-
ceptor subunits and IL-5 were used, preincubation (15 min at room 
temperature) of the proteins to achieve optimal IL-5 binding (the a-
receptor subunit at 3.2 mg/ml and IL-5 and P-receptor subunit at 
2 mg/ml) was carried out prior to addition to the transport assay (a 
subsequent dilution of 2 in 5). Image analysis of CLSM files and curve 
fitting to the equation FJc(t) = FJcmlaX(l— e
_ i i) were performed as 
described [20,25,27]. FJcmax is the maximal level of nuclear accumu-
lation whilst the first-order rate constant (k) is the rate at which FJ 
Cmax is reached. 
Fig. 1. Visualization of nuclear uptake of the hIL-5 P-receptor subunit in the absence and presence of hIL-5 and the hIL-5 a-receptor subunit 
in vitro. Results are shown for nuclear import of hIL-5-P-receptor-SFX preincubated (15 min, room temperature) in the absence (top left panel) 
or presence (top right panel) of unlabelled hIL-5 a-receptor subunit, unlabelled hIL-5 (middle left panel), or both (middle right panel), as indi-
cated, in mechanically perforated HTC cells after 12-16 min at room temperature. Results are compared to those for hIL-5-SFX (bottom pan-
els) in the absence and presence of unlabelled hIL-5 a- and P-receptor subunits, as indicated, after 6-8 min at room temperature. 
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3. Results 
3.1. IL-5 nuclear import in the presence of IL-5 receptor 
subunits 
To carry out subcellular localization studies, hIL-5 and 
soluble extracellular domain forms of the hIL-5 a- and P-
receptor subunits (see Section 2) were expressed in baculovi-
rus. Consistent with previous studies on the soluble form of 
the hIL-5 a-receptor subunit [28], a 1:1 complex between the 
extracellular domain of the hIL-5 a-receptor subunit and hlL-
5 was observed on non-denaturing polyacrylamide electropho-
retic gels (not shown); a complex of the P-receptor subunit 
extracellular domain with hIL-5 was not observed. 
hIL-5 was fluoresceinated with SFX as previously to yield a 
fluorescent derivative which retained biological activity [20], 
and nuclear import kinetics assessed in vitro, results being 
identical to those observed previously (Figs. 1 and 2, and 
see Table 1 for pooled data [20]). To test transport in the 
presence of the hIL-5 receptor subunits, hIL-5-SFX was al-
lowed to bind to unlabelled soluble a-receptor subunit in the 
presence of hIL-5 P-receptor subunit extracellular domain, 
and nuclear import assayed (Figs. 1 and 2; Table 1). No 
marked difference in the maximal nuclear accumulation of 
hIL-5-SFX was noted in the presence of receptor subunits 
compared to in their absence (Fig. 1, bottom panels; Fig. 2, 
top panel). The import rate, however, was about 50% slower 
(Table 1), implying that the receptor subunits may have 
bound to IL-5 and been cotransported to the nucleus through 
a piggy back mechanism [18,19,21-24], with the slower nu-
clear import kinetics attributable to the larger size of the 
protein complex compared to IL-5 alone. 
3.2. Nuclear co-import of IL-5 receptor subunits in the presence 
of IL-5 
The hIL-5 receptor subunits were labelled with SFX, and 
their nuclear import examined in the absence or presence of 
combinations of unlabelled hIL-5 and receptor subunits. Re-
sults for nuclear import of hIL-5 P-receptor-SFX are shown in 
Figs. 1 and 2. hIL-5 P-receptor-SFX alone did not accumulate 
in the nuclei of mechanically perforated HTC cells to any 
significant degree (FJcma:K of about 1, indicating equal con-
centrations in nucleus and cytoplasm, consistent with its mo-
lecular mass of ca. 40 kDa, below the cut-off value of 45 kDa 
for passive nuclear entry [18,19]), and did not show any 
marked nuclear uptake in the presence of either hIL-5 or 
hIL-5 a-receptor alone (Figs. 1 and 2). The latter was not 
unexpected, since the hIL-5 P-receptor is unable to bind IL-
5 in the absence of the a-receptor subunit. However, in the 
presence of both hIL-5 and the hIL-5 a-receptor, quite strik-
ing nuclear accumulation of hIL-5 P-receptor-SFX was ob-
served (Fig. 1, middle right panel), maximally to levels about 
3-fold those in the cytoplasm (see Fig. 2, bottom panel). The 
rate of accumulation was about 2.5-fold slower than that of 
hIL-5-SFX in the absence of receptor subunits (see Table 1), 
being both consistent with the uptake of a larger protein com-
plex, and comparable to that of ML-5-SFX in the presence of 
the a- and P-receptor subunits. The clear implication was that 
the hIL-5 P-receptor could be targeted to the nucleus by hIL-5 
through a piggy back mechanism requiring the hIL-5 binding 
a-receptor subunit in order to bring the p-subunit into the 
complex. 
Similar experiments were performed with labelled hIL-5 a-
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Fig. 2. Nuclear import kinetics of hIL-5 and the hIL-5 receptor sub-
units in the absence and presence of hIL-5 and receptor subunits in 
vitro. Quantitative results for the treatments described in Fig. 1 (see 
also Section 2) are shown for hIL-5-SFX (top panel), hIL-5 cx-recep-
tor-SFX (centre panel), and hIL-5 P-receptor-SFX (bottom panel), 
as indicated. Measurements were performed using image analysis as 
described in Section 2 [20] and represent the average of two sepa-
rate experiments, where each point represents the average of 5-7 
separate measurements for each of Fn and Fc, respectively, with au-
tofluorescence subtracted. Collated data are presented in Table 1. 
D.A. Jans et al.lFEBS Letters 410 (1997) 368-372 371 
Table 1 
In vitro nuclear import kinetics of hIL-5 and hIL-5 receptor subunits 
Protein Nuclear import parameter*1 
F Ic k (10"3) 
hIL-5-SFX 
hIL-5-SFX 
(+a- and P-receptor) 
hIL-5 a-receptor-SFX 
hIL-5 a-receptor-SFX 
(+(3-receptor) 
hIL-5 a-receptor-SFX 
(+hIL-5) 
hIL-5 a-receptor-SFX 
(+(3-receptor+hIL-5) 
hIL-5 P-receptor-SFX 
hIL-5 P-receptor-SFX 
(+a-receptor) 
hIL-5 P-receptor-SFX 
(+ML-5) 
hIL-5 P-receptor-SFX 
(+a-receptor+hIL-5) 
20 kDa dextran 
70 kDa dextran 
2.16±0.19 
1.86 ±0.06 
1.0610.04 
1.0510.05 
1.1810.04 
1.7310.05 
1.1410.18 
1.1710.08 
1.1010.05 
2.8110.19 
0.9410.03 
0.1610.03 
9241302 
6201108 
262138 
100120 
491183 
186128 
260170 
4601120 
190130 
370180 
NDC 
NDC 
lb 
lb 
lb 
lb 
2 
2 
2 
2 
a Raw data (see Fig. 2) were fitted for the function Fn/c(/)
 = ^VcmaxX(l—e~
H) [20,25,27], where FJcmax is the maximal level of accumulation at 
steady state in the nucleus, and / is time in min. An FJcma3i of 1.0 (e.g., 20 kDa dextran) indicates nuclear entry and equilibration between nucleus 
and cytoplasm, with values below 1 (e.g., 70 kDa dextran) indicating exclusion from the nucleus. The values shown are the mean 1 SEM, with 
n indicated. 
b SE from curve fit [25,27]. 
c ND, not determined. 
receptor (see Fig. 2 and Table 1). hIL-5 a-receptor-SFX did 
not accumulate significantly in the nucleus either in the pres-
ence or the absence of the P-receptor subunit or hIL-5 alone 
(Fig. 2, middle panel; Table 1). The combination of hIL-5 and 
P-receptor subunit had a marked effect, leading to maximal 
levels of nuclear accumulation of about 1.7-fold; the fact that 
accumulation under these conditions was not higher was at-
tributable to the fact that hIL-5 a-receptor-SFX was in a 
slight molar excess relative to IL-5 (see Section 2), and thus 
not all the a-receptor could bind stoichiometrically to IL-5 
and be piggy-backed into the nucleus. The fact that hIL-5 in 
the absence of the p-receptor subunit did not effect hIL-5 a-
receptor-SFX nuclear import implied that the high affinity 
receptor (i.e., a- and P-subunits) was required for the latter, 
due to the fact either that the lower affinity of the a-receptor-
subunit alone for ligand was insufficient to enable piggy back 
transport of the a-receptor-subunit, or that the trimeric com-
plex as such was required for cotransport. Overall, the results 
strongly supported the idea that the hIL-5 receptor subunits 
can be cotargeted to the nucleus by IL-5. 
4. Discussion 
A variety of studies have put the traditional concept of 
hormone/cytokine action being exclusively confined to events 
at the level of the membrane into question, with clear evidence 
for significant nuclear signalling roles for ligands such as pro-
lactin, platelet derived growth factor (PDGF), fibroblast 
growth factor (FGF), growth hormone (GH) and insulin 
(see Ref. [17]). Like molecules of the PDGF and FGF classes 
[17,29,30], IL-5 possesses a functional NLS and is able to 
target to the nucleus in intact receptor-expressing cells [20]. 
Nuclear targeting of IL-5 may be the basis of IL-5's highly 
specific signal transduction role with respect to regulation of 
the eosinophil lineage and recruitment of eosinophils to the 
sites of inflammation, additional to the signalling functions it 
shares with IL-3 and GM-CSF through the common P-recep-
tor subunit. 
Although IL-5 is of sufficiently small size not formally to 
require an NLS in order to enter the nucleus, the fact that its 
NLS is capable of targeting the heterologous protein p-galac-
tosidase (476 kDa) to the nucleus both in vivo and in vitro 
[20] implies that the NLS may be functionally important in 
the context of a protein complex larger in size than IL-5 
alone. Our results for a- and p-receptor subunit cotransport 
to the nucleus in vitro by hIL-5 here strongly imply that the 
IL-5-NLS may be required to enable the nuclear entry of the 
a- and P-receptor subunits in a ligand-receptor complex. 
Membrane forms of other polypeptide hormone receptors 
such as those for IL-1 and nerve growth factor can be found 
in the nucleus subsequent to endocytosis at the plasma mem-
brane ([31,32]; see Ref. [17]), and it seems likely that the 
membrane-associated IL-5 receptor subunits could follow a 
similar pathway. 
Based on the results here, a possible role of IL-5 in the 
nucleus would appear to be to target its receptor subunits 
to the nucleus, where they could modulate gene expression 
through modifying the activity of nuclear TFs; eg. through 
binding of the IL-5 P-receptor subunit to SH2/SH3 domain-
carrying proteins. Nuclear receptor subunits could thus mod-
ulate nuclear tyrosine phosphorylation, and thereby act in 
analogous fashion to prolactin which, subsequent to recep-
tor-mediated endocytosis [33], appears to have a specific signal 
transduction role in the nucleus through activating nuclear 
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PK-C [34]. Alternatively, IL-5 together with its receptor sub-
units may be directly involved in binding to chromatin, pos-
sibly in analogous fashion to G H which, together with the 
soluble G H binding protein form of the G H receptor, may 
bind specific D N A sequence elements directly [35,36]. 
In summary, this study represents the first formal, direct 
demonstrat ion of nuclear protein piggy back transport in vi-
tro. Our observations raise the possibility that the primary 
role of IL-5 nuclear targeting is to cotransport its receptor 
subunits, and perhaps other complexed signalling molecules, 
to the nucleus. Future work in this laboratory will seek to 
determine the precise signalling role of IL-5, together with 
its specific receptor subunits, in the nucleus. 
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